Global Enfortumab Vedotin‑ejfv Market Strategic Research Report

Scope of the Report

The global Enfortumab Vedotin‑ejfv market size is predicted to grow from US$ 1,898 million in 2025 to US$ 5,390 million in 2032; it is expected to grow at a CAGR of 14.3% from 2026 to 2032.

Vandetanib is an oral small molecule tyrosine kinase inhibitor primarily used for the treatment of medullary thyroid cancer (MTC). It works by inhibiting multiple tyrosine kinases associated with cancer cell growth and metastasis, such as epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), and the RET proto-oncogene, thereby suppressing tumor growth and angiogenesis, leading to an anti-tumor effect. Vandetanib can be used alone or in combination with other therapeutic regimens and has shown significant efficacy in the treatment of advanced or metastatic MTC. This drug is typically used in cancer patients whose disease cannot be controlled by conventional therapies and has been approved for clinical use in certain countries and regions.In 2025, global Vandetanib production reached approximately 450,000 bottles.

Vandetanib (Vandetanib) is a tyrosine kinase inhibitor primarily used to treat medullary thyroid cancer (MTC). With the growing global demand for cancer treatments, particularly in the field of advanced and metastatic cancer treatment, the market prospects for Vandetanib remain promising. In recent years, the diagnostic rate of medullary thyroid cancer has increased, and the limitations of traditional treatments in controlling advanced MTC have led to the gradual emergence of targeted drugs like Vandetanib as a new treatment option.The market demand for Vandetanib primarily comes from MTC patients, especially those for whom traditional therapies are ineffective or surgery cannot be used. Although the drug has been approved and entered markets in certain countries and regions, its high cost and market competition have limited its market penetration. With the rapid development of targeted therapies and the emergence of new-generation cancer drugs, Vandetanib faces intense competition from other treatment options, such as immunotherapies and molecular targeted drugs.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Enfortumab Vedotin‑ejfv market?

What factors are driving Enfortumab Vedotin‑ejfv market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Enfortumab Vedotin‑ejfv market opportunities vary by end market size?

How does Enfortumab Vedotin‑ejfv break out by Type, by Application?

This report presents a comprehensive overview of the global Enfortumab Vedotin‑ejfv market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 100 mg
• 300 mg

Segment by Combination Therapy

• Enfortumab vedotin + Pembrolizumab
• Enfortumab vedotin + platinum-based chemotherapy

Segment by Sales Channel

• Hospital
• Retail
• Online

Segment by Application

• Advanced Urothelial Cancer
• Advanced Medullary Thyroid Cancer (MTC)
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Enfortumab Vedotin‑ejfv market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Advanced Urothelial Cancer, Advanced Medullary Thyroid Cancer (MTC), Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact